GPT and hepatocellular carcinoma: HBsAg-positive patients with high levels of serum HBV DNA and alanine aminotransferase (ALT) are targets of anti-viral therapies because they are at high risk of liver cirrhosis and hepatocellular carcinoma (HCC) [1].